Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Levoxyl (levothyroxine sodium) tablets Recalled by King Legacy, a wholly owned subsidiary of Pfizer Due to Subpotent Drug: The products were below specification for...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact King Legacy, a wholly owned subsidiary of Pfizer directly.
Affected Products
Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-count bottles (NDC 60793-855-01) and b) 1000-count bottles (NDC 60793-855-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620
Quantity: 107,236 bottles
Why Was This Recalled?
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About King Legacy, a wholly owned subsidiary of Pfizer
King Legacy, a wholly owned subsidiary of Pfizer has 11 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report